Methyldopa 250mg tablets

Krajina: Spojené kráľovstvo

Jazyk: angličtina

Zdroj: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktívna zložka:

Methyldopa (anhydrous)

Dostupné z:

Waymade Healthcare Plc

ATC kód:

C02AB01

INN (Medzinárodný Name):

Methyldopa (anhydrous)

Dávkovanie:

250mg

Forma lieku:

Oral tablet

Spôsob podávania:

Oral

Trieda:

No Controlled Drug Status

Typ predpisu:

Valid as a prescribable product

Prehľad produktov:

BNF: 02050200

Príbalový leták














“


”




















Súhrn charakteristických

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Methyldopa 250 mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 250 mg of methyldopa (anhydrous).
For the full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
Yellow, round, film coated tablets, embossed with “MT/250”
separated by a
breakline.
The breakline is not intended for breaking the tablet.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the treatment of hypertension.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
_Use in Adults _
_Initial dosage: _Usually 250 mg two or three times a day, for two
days.
_ _
_Adjustment: _Usually adjusted at intervals of not less than two days,
until an
adequate response is obtained. The maximum recommended daily dosage is
3
g.
Many patients experience sedation for two or three days when therapy
is
started or when the dose is increased. When increasing the dosage,
therefore, it
may be desirable to increase the evening dose first.
Withdrawal of methyldopa is followed by return of hypertension,
usually
within 48 hours. This is not complicated generally by an overshoot of
blood
pressure.
_Patients with renal impairment:_
Methyldopa is largely excreted by the kidney, and patients with
impaired renal
function may respond to smaller doses.
_Other antihypertensives: _
Methyldopa therapy may be initiated in most patients already on
treatment
with other antihypertensive agents by terminating these other
antihypertensive
medications gradually if required. Following such previous
antihypertensive
therapy, methyldopa should be limited to an initial dose of not more
than 500
mg daily and increased as required at intervals of not less than two
days.
When methyldopa is given to patients on other antihypertensives, the
dose of
these agents may need to be adjusted to effect a smooth transition.
When 500 mg of methyldopa is added to 50 mg of hydrochlorothiazide,
the
two agents may be given together once daily.
_Paediatric population:_
Initial dosage is based on 10